Case Study 2: Options for Patients With Rheumatoid Arthritis Who Do Not Adequately Respond to a TNF Inhibitor CME

Allan Gibofsky, MD, JD, FACP, FCLM Author Information and Disclosures

Release Date: May 16, 2008; Valid for credit through May 16, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

This CME program was created for use on eMedicine.com.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

This activity is Part 2 of: Current Strategies for the Management of Patients With Rheumatoid Arthritis in the Era of Biologic Therapy: A Case Study Series

Related Link
Case Study 1: Options for Patients With Newly Diagnosed Rheumatoid Arthritis Who Do Not Adequately Respond to Methotrexate

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 education | outcomes | science
BMS
Learning Objectives
Upon completion of this activity, participants should be better able to:
  • Discuss the therapeutic options for patients who failed therapy with either methotrexate or TNF inhibitors, based on the latest data from biologic clinical trials
  • Identify challenges faced by clinicians when choosing a therapeutic strategy in RA
  • Define and respond to treatment failures in practice
Author Disclosures
Allan Gibofsky, MD, JD, FACP, FCLM
Disclosure: Speaker and/or stock owner: Abbott Laboratories, Bristol-Myers Squibb, Pfizer Inc, Wyeth.
 
education | outcomes | science
education | outcomes | science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

education | outcomes | science designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.